| Designations: |
NCI-H128 [H128] |
| Depositors: |
AF Gazdar |
| Biosafety Level: |
1 |
| Shipped: |
frozen |
| Medium & Serum: |
See Propagation |
| Growth Properties: |
floating aggregates |
| Organism: |
Homo sapiens |
| Morphology: |
floating aggregates
|
| Source: |
Organ: lung
Disease: carcinoma; small cell lung cancer
Derived from metastatic site: pleural effusion |
| Permits/Forms: |
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. |
| |
| Tumorigenic: |
Yes |
| DNA Profile (STR): |
Amelogenin: X
CSF1PO: 10
D13S317: 12
D16S539: 13
D5S818: 9
D7S820: 8,10
THO1: 6,9
TPOX: 8
vWA: 17 |
| Cytogenetic Analysis: |
There are 2 distinct aneuploid peaks, both have characteristic 3p deletion. |
| Isoenzymes: |
AK-1, 1
ES-D, 1
G6PD, A
GLO-I, 1-2
Me-2, 1
PGM1, 1
PGM3, 1 |
| Age: |
60 years |
| Gender: |
male |
| Ethnicity: |
Black |
| Comments: |
This cell line is aneuploid.
Will form colonies in soft agar.
It retains small cell carcinoma morphology and ultrastructure as well as APUD cell characteristics.
NCI-H128 cells do well on a rotary shaker flask at 70 to 80 rpm at 37C.
It is normal for cultures of this line to have fairly large amounts of cell debris. |
| Propagation: |
ATCC complete growth medium: RPMI 1640 medium, 80%; fetal bovine serum, 20% - OR - Iscove's modified Dulbecco's medium, 80%; fetal bovine serum, 20%
|
| Subculturing: |
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Medium Renewal: Twice per week
Allow cell aggregates to settle to the bottom of the flask, discard the supernatant medium, disperse the cells with gentle pipetting and dispense into new flasks. Subculture every 6 to 8 days. |
| Preservation: |
Culture medium, 90%; DMSO, 10% |
| Related Products: |
normal (or near-normal) cell line established from the same patient:ATCCCRL-5947 |
| References: |
1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed:6646201
23036: Gazdar AF, et al. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40: 3502-3507, 1980. PubMed: 6108156
23037: . . Cancer Res. 40: 4556-4563, 1980.
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23057: Gazdar AF, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. Cancer Res. 45: 2924-2930, 1985. PubMed: 2985258
23080: Hensel CH, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 50: 3067-3072, 1990. PubMed: 2159370
32276: Cairns P, et al. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions. Cancer Res. 57: 5356-5359, 1997. PubMed: 9393760 |
|
